Although the potential therapeutic relevance of modulating the expression/activity of AHSG, ANGPTL4, LECT2 and FGF21 for treating obesity, IR and liver metabolic disorders is still unclear, targeting these hepatokines appears to be a promising strategy in addition to other currently used therapies. Here, FGF21 is linked to obesity disorder.